Psychedelics & Cannabis

Timothy W. Fong, MD, touches on our current understanding about cannabis use for psychiatric disorders.

Research on psilocybin, LSD, and other hallucinogens as psychiatric treatments are in their renaissance, transitioning from banned and illegal to potentially useful in changing life for the better in some patients. More in this podcast.

Research on psychiatrists' attitudes on the potential of cannabis in psychiatry.

Enlightening survey results reveal what psychiatrists think about medical marijuana/cannabis use, how or whether to discuss with their patients, and what biases might get in the way of such conversations.

The sharply decreasing perception of risk and easy accessibility of cannabis has many patients turning towards it, despite the potential negative effects.

Cannabis use has prompted symptoms such as dizziness, sleepiness, and fatigue in older patients. Are there any benevolent effects?

The rapidly changing field of cannabinoids and their clinical implications poses a particular challenge in psychiatry.

Early studies find psilocybin shows promise for some psychiatric disorders...

A synthesis of quantitative reviews on the relationship between cannabis use and psychosis.

The conversation about cannabis is happening now.

Research on a new kind of cannabis treatment prepares to move forward.

What are your thought about navigating these uncharted waters?

What are your thoughts about prescribing medical marijuana/cannabis to treat psychiatric disorders?

The word cannabis does not tell us a whole lot, only that it came from that plant. What about the 100+ unexplored cannabinoids, and other unknowns?

What are your feelings about the utility of cannabis in psychiatric practice?

As our knowledge about herbal cannabis, the endocannabinoid system, and cannabinoid pharmacology expands, should psychiatrists discuss these issues with their patients?

New research is being conducted on how psychedelic substances may change the future of mental health care. Dr Carlin explained more in her speech at the Annual Psychiatric Times® World CME Conference™.

An exploration of findings from contemporary research that hint at the unexplored hallucinogenic potential of ketamine and considerations for future investigation.

Here: a review of the scientific evidence relevant to the use of classic hallucinogens in the treatment of substance use disorders.

While research suggests that cannabis use can induce an acute psychotic state, there is controversy about whether it may precipitate psychotic disorders, such as schizophrenia. These authors offer an update on this important issue and provide clinically useful recommendations.